General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded without agreement
Manufacturer:
Chiesi Canada Corporation
Indication:
Transfusional iron overload due to sickle cell disease or other anemias
Last updated October 27, 2023
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Systemic lupus erythematosus
Last updated October 25, 2023
Status:
Concluded with an LOI
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Unresectable or metastatic uveal melanoma in adult patients who are Human leukocyte antigen (HLA)-A*02:01-positive
Last updated October 23, 2023
Lutathera (lutetium 177 dotatate)
Status:
Concluded with an LOI
Manufacturer:
Advanced Accelerator Applications
Indication:
Unresectable or metastatic, well-differentiated, somatostatin receptor (SSR)-positive pancreatic neuroendocrine tumours (pNETs) in adults whose disease has progressed after treatment with a somatostatin analogue (SSA), unless there is a contraindication or intolerance
Last updated October 17, 2023
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Episodic migraine in adults (prevention)
Last updated October 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Alexion Pharma GmbH
Indication:
Atypical hemolytic uremic syndrome
Last updated October 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Alexion Pharma GmbH
Indication:
Paroxysmal nocturnal hemoglobinuria (PNH)
Last updated October 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Diabetes mellitus in patients who require insulin for the control of hyperglycemia (normally to be used in regimens together with an intermediate or long-acting insulin), or continuous subcutaneous insulin infusion (CSII) in pump systems which are licensed in Canada for Trurapi insulin infusion
Last updated October 10, 2023
Status:
Negotiations were not pursued
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Last updated October 6, 2023
Status:
Concluded with an LOI
Manufacturer:
Lupin Pharma Canada Ltd.
Indication:
Ankylosing Spondylitis, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis and Polyarticular Juvenile Idiopathic Arthritis
Last updated October 4, 2023